Read Article
Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent. Luspatercept-aamt (Reblozyl), a recombinant fusion protein that binds transforming growth factor beta superfamily ligands to reduce SMAD2 and SMAD3 signaling, was approved by the FDA in November 2019 and has been studied in this patient population with promising results.
Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?
Engage Healthcare Communications, LLC, is a privately held publishing and medical communications company located in Cranbury, New Jersey. The owners of Engage Healthcare Communications, in cooperation with the Editor-in-Chief, Editorial Director, and Editorial Advisory Board members, have more than 60 years of combined experience in successfully launching, managing, and executing high-quality, scholarly journals.
In addition to Value-Based Cancer Care™, Engage Healthcare Communications also publishes the following journals:
Senior Vice President/Group PublisherNicholas Englezos This email address is being protected from spambots. You need JavaScript enabled to view it.
Vice President/Group PublisherRussell Hennessy This email address is being protected from spambots. You need JavaScript enabled to view it.
Editorial DirectorDalia Buffery This email address is being protected from spambots. You need JavaScript enabled to view it.
Associate EditorLara J. Lorton
Editorial AssistantCara Guglielmon
Production ManagerMelissa Lawlor
Submit
Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.
